Referred to the House Committee on Energy and Commerce.
The bill bars the Department of Health and Human Services, including the FDA, from treating pregnancy as an illness when approving abortion drugs or imposing REMS. It nullifies any drug approvals that relied on treating pregnancy as an illness, explicitly including the current mifepristone approval.
Liberals emphasize public-health and FDA-science harms; conservatives emphasize restricting abortion drug approvals.
Relative to its intended legislative type, this bill clearly states a narrow substantive policy objective and identifies the affected statutory provisions, but it lacks definition of key terms, procedural mechanisms for rescinding approvals, fiscal analysis, handling of edge cases, and accountability measures.
The bill bars the Department of Health and Human Services, including the FDA, from treating pregnancy as an illness when approving abortion drugs or imposing REMS.
It nullifies any drug approvals that relied on treating pregnancy as an illness, explicitly including the current mifepristone approval.
Directly targets a divisive issue, removes key approvals without compromise, and invites litigation—low odds absent strong chamber alignment.
Relative to its intended legislative type, this bill clearly states a narrow substantive policy objective and identifies the affected statutory provisions, but it lacks definition of key terms, procedural mechanisms for rescinding approvals, fiscal analysis, handling of edge cases, and accountability measures.
Liberals emphasize public-health and FDA-science harms; conservatives emphasize restricting abortion drug approvals.
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberals emphasize public-health and FDA-science harms; conservatives emphasize restricting abortion drug approvals.
Likely strongly opposed.
They would view the measure as undermining FDA scientific standards and removing legal authorization for a widely used medication abortion drug.
They would see public-health and access harms for pregnant people, especially those with limited clinical options.
Mixed and cautious.
They would be concerned about disrupting FDA authority and patient safety while understanding political aims to restrict abortion access.
They would want clearer legal drafting and evidence of narrow scope before supporting.
Likely supportive.
They would view the bill as restricting abortion by preventing regulatory classification of pregnancy as an illness, and as a legislative tool to revoke mifepristone approval.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Directly targets a divisive issue, removes key approvals without compromise, and invites litigation—low odds absent strong chamber alignment.
The bill has not accumulated any surfaced votes yet.
Liberals emphasize public-health and FDA-science harms; conservatives emphasize restricting abortion drug approvals.
Directly targets a divisive issue, removes key approvals without compromise, and invites litigation—low odds absent strong chamber alignmen…
Relative to its intended legislative type, this bill clearly states a narrow substantive policy objective and identifies the affected statutory provisions, but it lacks definition of key terms, procedural mechanisms for…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.